Exploratory Visual Analysis of Statistical Results from Microarray Experiments Comparing High and Low Grade Glioma by Reif, David M. et al.
Cancer Informatics 2007:5 19–24 19
SYSTEMS BIOLOGY SPECIAL ISSUE
Correspondence: Jason H. Moore, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, 
NH 03756. Tel: 603-653-9939; Fax: 603-653-9900; Email: jason.h.moore@dartmouth.edu 
Please note that this article may not be used for commercial purposes. For further information please refer to the copyright 
statement at http://www.la-press.com/copyright.htm
Exploratory Visual Analysis of Statistical Results from 
Microarray Experiments Comparing High and Low Grade 
Glioma
David M. Reif
1, Mark A. Israel
2 and Jason H. Moore
3
1Graduate Student, Computational Genetics Laboratory, Dartmouth-Hitchcock Medical Center, Leba-
non, NH 03756. 
2Professor of Pediatrics and Genetics, Director, Norris-Cotton Cancer Center, Dart-
mouth-Hitchcock Medical Center, Lebanon, NH 03756. 
3Frank Lane Research Scholar in Computa-
tional Genetics, Associate Professor of Genetics, 706 Rubin Building HB 7937; Dartmouth-Hitchcock 
Medical Center, One Medical Center Drive, Lebanon.
Abstract: The biological interpretation of gene expression microarray results is a daunting challenge. For complex 
diseases such as cancer, wherein the body of published research is extensive, the incorporation of expert knowledge provides 
a useful analytical framework. We have previously developed the Exploratory Visual Analysis (EVA) software for 
exploring data analysis results in the context of annotation information about each gene, as well as biologically relevant 
groups of genes. We present EVA as a ﬂ  exible combination of statistics and biological annotation that provides a straight-
forward visual interface for the interpretation of microarray analyses of gene expression in the most commonly occuring 
class of brain tumors, glioma. We demonstrate the utility of EVA for the biological interpretation of statistical results by 
analyzing publicly available gene expression proﬁ  les of two important glial tumors. The results of a statistical comparison 
between 21 malignant, high-grade glioblastoma multiforme (GBM) tumors and 19 indolent, low-grade pilocytic 
astrocytomas were analyzed using EVA. By using EVA to examine the results of a relatively simple statistical analysis, we 
were able to identify tumor class-speciﬁ  c gene expression patterns having both statistical and biological signiﬁ  cance. Our 
interactive analysis highlighted the potential importance of genes involved in cell cycle progression, proliferation, signaling, 
adhesion, migration, motility, and structure, as well as candidate gene loci on a region of Chromosome 7 that has been 
implicated in glioma. Because EVA does not require statistical or computational expertise and has the ﬂ  exibility to accom-
modate any type of statistical analysis, we anticipate EVA will prove a useful addition to the repertoire of computational 
methods used for microarray data analysis. EVA is available at no charge to academic users and can be found at 
http://www.epistasis.org.
Abbreviations: EVA: Exploratory Visual Analysis; GBM: glioblastoma multiforme; GUI: graphical user interface; 
GO: Gene Ontology; ANOVA: analysis of variance.
Keywords: glioma, gene expression microarray, statistics, biological interpretation, visualization, annotation databases.
Introduction
Modern experimental techniques such as microarray analysis of gene expression are improving our 
understanding of both the classiﬁ  cation and biological basis of complex diseases. While there has been 
an explosion in the volume of raw data available for analysis, there is a widening gap between statisti-
cally compelling results and their biological interpretation. Research oftentimes becomes bogged down 
in an analytical maze of spreadsheets and arbitrary statistical signiﬁ  cance thresholds. Tools are needed 
that can efﬁ  ciently summarize huge amounts of information within a biological context. EVA’s novel 
combination of features supports such a comprehensive analysis. Combining ﬂ  exibility, speed, and 
visualization of both statistical and annotative information into a single package, EVA fulﬁ  lls a crucial 
role in comprehensive microarray analysis.
Here, we apply EVA to the study of glioma. These tumors arise in glial cells of the central nervous 
system and among many different functions, provide support, nourishment, and insulation to neurons in 
the brain (Odreman et al. 2005). Although rare, glioma account for approximately 45% of primary brain 
tumors (Legler et al. 1999). Astrocytoma, the most common subtype of glioma, arise in astrocytes. These 
tumors are classiﬁ  ed into grades I–IV according to World Health Organization guidelines (Kleihues et al. 
2002). Grade IV is highly-aggressive and also known as glioblastoma multiforme (GBM). Grade I is much Cancer Informatics 2007:5 20
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less aggressive and commonly refered to as pilocytic 
astrocytoma. GBMs have a heterogeneous pathology 
and may develop from a lower-grade astrocytoma 
or appear to arise de novo (Odreman et al. 2005). 
Intermediate grades of glioma differ primarily in 
terms of their apparent proliferative rates and the 
aggressiveness with which they appear to inﬁ  ltrate 
normal tissue. The treatment of varying grades of 
astrocytic glioma varies considerably, though the 
histologic basis on which these are differentiated is 
subtle and oftentimes confusing. The accurate diag-
nosis of glioma subclasses will become increasingly 
important as treatments become more speciﬁ  c and 
more effective. The elucidation of a molecular 
signature for such tumors, and especially GBM, 
should provide insights of both pathological and 
therapeutic signiﬁ  cance and can be expected to 
enhance current diagnostic practice and facilitate 
the development of improved treatments.
Methods
Overview of the EVA software 
package
Visualization is the key design concept that allows 
EVA to rationally condense the vast amounts of 
information emerging from microarray based 
analyses of gene expression. In his work on visual-
izing quantitative information, Tufte states that 
“the most effective way to describe, explore, and 
summarize a set of numbers—even a very large 
set—is to look at pictures of those numbers” (Tufte 
2001). With this philosophy in mind, EVA is 
controlled via a custom graphical user interface 
(GUI) that provides real-time updates to the global 
results display, while keeping all features of the 
software at the user’s ﬁ  ngertips. Through simple 
manipulation of both the density and type of infor-
mation displayed, visual patterns of gene expres-
sion can be developed.
The user simply downloads the desktop client 
and requests a secure account, which provides a 
portal to the EVA web server via the custom GUI. 
This architecture provides ease of security, distrib-
utability, and expandability. Thus, once the user 
has downloaded the client, updates or expansions 
of the EVA modules are transparent from the user’s 
perspective. Upon opening the software, login 
grants the user access to interfaces for various 
administrative tasks, including creating, updating, 
deleting, or loading experiments and results. 
Individual users can access only those experiments 
for which they have permission, meaning that 
unless a group of collaborators has chosen to share 
a user account, a particular experiment is accessible 
only to the researcher who created it. Once a new 
experiment has been deﬁ  ned or an existing exper-
iment selected, all of the results and links for that 
experiment are loaded for viewing on the user’s 
desktop.
EVA is designed to be ﬂ  exible and support a 
wide range of research goals—allowing a truly 
exploratory analysis. The software can handle any 
kind of statistical result(s) for any number of 
experiments. Rather than being limited by those 
statistics implemented in the software, the user is 
free to use any statistic of choice or to deﬁ  ne a 
custom statistic. When a ﬁ  le of gene or probe 
identifiers and associated statistical results is 
uploaded, the user speciﬁ  es the parameters for each 
of the statistics in that ﬁ  le. Dialog boxes allow the 
user to choose amongst a list of pre-deﬁ  ned statis-
tics (such as t-test p-value, fold change, etc.) or to 
deﬁ  ne custom statistics representing that user’s 
particular analysis. EVA’s graphical results display 
can be organized into nested groupings for any 
combination of six biological categories: Gene 
Ontology (GO), Biopath, Domain, Map Location, 
Chromosome, and Phenotype (Harris et al. 2004; 
Kanehisa et al. 2004; Marchler-Bauer et al. 2003; 
McKusick-Nathans Institute for Genetic Medicine 
2004; Pruitt and Maglott, 2001). The permutation 
testing procedure described in (Reif et al. 2005) is 
used to assess the statistical signiﬁ  cance of certain 
biological groups that contain a higher proportion 
of differentially expressed genes relative to other 
groups. The permutation p-value represents the 
probability of obtaining the observed number of 
differentially expressed genes within the selected 
signiﬁ  cance range in a given annotative category 
due to chance alone. As a complement to statistical 
analysis, EVA links to multiple annotation sources 
via Entrez Gene (Maglott et al. 2005). This aspect 
affords immediate evaluation of the biological 
relevance of candidate genes or groups of genes. 
To ensure that the user can replicate ﬁ  ndings, EVA 
incorporates a printable command log feature into 
the GUI.
Speed enhances the interactivity of EVA’s ﬂ  ex-
ible interface. Switching between annotative 
groupings, statistics, significance levels, and 
display modes occurs seamlessly, because all of 
the data and links are loaded into memory upon Cancer Informatics 2007:5 21
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opening the software. While this design increases 
loading time, it allows immediate manipulation of 
the display once the initial loading is completed. 
Thus, performance is not limited by demand on 
the web server—negating the query lag time typical 
of other analysis packages.
A more complete description of the EVA inter-
face and its capabilities is given in (Reif et al. 2005; 
Reif and Moore, 2006), and a comprehensive, 
illustrated help menu is included with the software. 
It is important to note that the EVA database is 
designed to store statistical results (e.g. p-values) 
and not raw microarray data. Since no patient 
identifying information is stored with the summary 
statistics, there are no conﬁ  dentiality concerns with 
the database.
Microarray data
The microarray dataset to which we applied EVA 
in this study is described fully in (Rickman et al. 
2001) and is publicly available at the National 
Cancer Institute’s Gene Expression Data Portal 
(http://gedp.nci.nih.gov/dc/index.jsp). Forty 
primary glioma were obtained from surgery 
patients (with informed consent) at the University 
of Michigan Medical Center. Total RNA was 
isolated from these samples, which included 21 
GBMs and 19 pilocytic astrocytomas. Expression 
was measured on HuGeneFL oligonucleotide chips 
from Affymetrix. Normalization and ﬁ  ltering were 
carried out as described in (Rickman et al. 2001), 
leaving approximately 4600 genes for statistical 
analysis.
Application of EVA to glioma 
microarray results
Genes that discriminate GBMs from pilocytic astro-
cytomas were identiﬁ  ed by the original authors using 
a combination of analysis of variance (ANOVA) and 
fold-change differences between tumor classes. 
One-way ANOVA models were ﬁ  t with separate 
means for each tumor class. An F test was performed 
for each gene to test the hypothesis that the normal-
ized mean expression of that gene is identical in both 
tumor classes. The resulting p-value represents the 
probability that the observed difference in expression 
between tumor classes is due to chance alone. As in 
(Rickman et al. 2001), fold-changes in measured 
expression levels of 1.5X or greater (p-value < 0.01) 
were considered signiﬁ  cant. From these results, we 
deﬁ  ned three statistics for EVA. For each gene on 
the array, the three statistics loaded into EVA were: 
1) the F test p-value, 2) the gene coded according to 
whether it had a significant fold-change and 
p-value < 0.01 or not, and 3) the gene coded 
according to whether it had a signiﬁ  cant negative 
fold-change and p-value < 0.01, signiﬁ  cant positive 
fold-change and p-value < 0.01, or neither. See 
Figure 1 for a summary of our application of EVA.
Results
EVA eliminates the traditional post-hoc 
assignment of biological relevancy
By using EVA to examine the results of a relatively 









1. F test p-value
2. Significant fold-change
and F test p-value < 0.01
3. Significant positive or
negative fold-change and
F test p-value < 0.01
Figure 1. Genes whose expression levels discriminate between GBMs and pilocytic astrocytomas were identiﬁ  ed using a combination of 
analysis of variance (ANOVA) and fold-change differences between tumor classes. These results were given to EVA as three separate 
statistics for each gene on the array: 1) the F test p-value, 2) the gene coded according to whether it had a signiﬁ  cant fold-change and 
p-value < 0.01, and 3) the gene coded according to whether it had a signiﬁ  cant negative fold-change and p-value < 0.01 or signiﬁ  cant 
positive fold-change and p-value < 0.01.Cancer Informatics 2007:5 22
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tumor class-specific gene expression patterns 
having simultaneous statistical and biological 
signiﬁ  cance (see Figure 2). In contrast, a typical 
microarray analysis demands a great deal of exper-
tise in bioinformatics and requires the researcher 
to bridge the usual gap between statistical results 
and biological knowledge. EVA sheds light on 
ﬁ  ndings that would have been missed by rigid 
statistical signiﬁ  cance thresholds. The novel utility 
of EVA in bringing together a complementary set 
of visual, statistical, and annotative analysis tools 
is supported by the results described below.
Biological patterns identiﬁ  ed using EVA
Visualization of meaningful patterns in a sea of 
experimental results is EVA’s fundamental purpose. 
With the results organized according to Gene 
Ontology (GO), it is immediately apparent that the 
“cell adhesion” and “cell proliferation” groups 
have a relatively high number of highlighted gene 
squares (see Figure 2). Here, the EVA display is 
organized to highlight genes that have a fold-
change difference greater than 1.5 and p-value 
< 0.01. Performing a permutation test on these 
categories statistically veriﬁ  es this visual impres-
sion that the “cell adhesion” and “cell proliferation” 
groups are enriched with respect to the number of 
differentially expressed genes they contain. This 
conclusion also makes intuitive biological sense, 
since it is known that genes involved in cell adhe-
sion and proliferation are differentially expressed 
in aggressive GBMs and low grade pilocytic astro-
cytomas (Muracciole et al. 2002).
The simple point-and-click interface for statis-
tically testing the relative over-abundance of 
differentially expressed genes within certain 
biological groups is a useful mechanism for scan-
ning an entire dataset in one sweep. Those groups 
having a greater proportion of differentially 
expressed genes than would be expected by chance 
are highlighted in the EVA log and can be written 
to an external ﬁ  le for further analysis. Using this 
strategy, interesting groups of genes involved in 
cellular migration, motility, and structure were 
identiﬁ  ed. The GO groups “extracellular matrix,” 
“cytoskeleton organization and biogenesis,” and 
“metalloendopeptidase inhibitor activity,” as well 
as conserved protein Domain (from NCBI’s 
Conserved Domain Database) groups containing 
genes involved in cellular structure, were all 
signiﬁ  cantly down-regulated. Aggressive tumors 
such as GBMs show altered expression of matrix 
metalloproteinases and other genes involved in 
regulation of cellular structure and motility 
(Odreman et al. 2005; Wick, Platten and Weller, 
2001). Notably, other biologically plausible catego-
ries, such as the GO group “heterophilic cell adhe-
Figure 2. Each square represents the p-value for a particular gene, organized according to Gene Ontology. The “cell adhesion” and “cell 
proliferation” groups have a relatively high number of highlighted gene squares, meaning that they contain a number of genes that have a 
fold-change difference greater than 1.5 and p-value < 0.01. The results of permutation tests that statistically verify this visual impression are 
listed in the log.Cancer Informatics 2007:5 23
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sion” and the Domain group “Tubulin,” had 
permutation p-values just beyond the traditional 
0.05 signiﬁ  cance threshold and would have been 
missed by a purely statistical analysis. Employing 
EVA’s direct link that allows the annotation of 
individual genes (via Entrez Gene), we were able 
to identify biologically relevant candidate genes 
in these marginally signiﬁ  cant groups. Many of the 
genes in these groups also had marginally signiﬁ  -
cant individual statistical results. For example, 
disruption of microtubule dynamics by genes in 
the “Tubulin” group can affect apoptotic pathways 
(Yan et al. 2001).
EVA naturally incorporates expert knowledge 
into the statistical analysis via its biologically-
organized display and links to gene-speciﬁ  c anno-
tation. In an analysis of different histologic grades 
of brain tumors, it is reasonable to assume that 
differences in expression proﬁ  les of low- versus 
high-grade tumors might reﬂ  ect alterations in cell 
cycle progression and cell signaling. Indeed, many 
differentially expressed genes appear in the related 
cell cycle GO groups “regulation of cell cycle,” 
“cytokinesis,” “mitosis,” and “oncogenesis” as 
well as the related cell signaling GO groups “JNK 
cascade,” “protein kinase activity,” and “GTPase 
activity.” Biopath groups “cell cycle” and “MAPK 
signaling” are also enriched. Additionally, Domain 
groups involving growth factor receptors contain 
many genes identiﬁ  ed as signiﬁ  cant. EVA’s permu-
tation testing capabilities lend statistical signiﬁ  -
cance to the observed high number of differentially 
expressed genes in these biological groups.
Further illustration of how EVA can tie together 
multiple lines of evidence in support of plausible 
biological conclusions or promising future research 
directions is the identification of regions on 
Chromosome 7 where candidate genes of interest 
might be located. Visual inspection and permuta-
tion testing identiﬁ  ed chromosomal map region 
7q21-7q32 as having a high frequency of differen-
tially expressed genes. Chromosomal abnormali-
ties on this chromosome have been implicated in 
glioma (Squire et al. 2001). This region includes 
the loci for Zyxin (a messenger in the signal trans-
duction pathway that mediates adhesion-stimulated 
changes in gene expression) and HIPK2 
(participates in the TGF-beta signaling pathway 
leading to JNK activation and apoptosis) (Hofmann 
et al. 2003; Li, Zhuang and Trueb, 2004). Corrob-
orating evidence for the importance of genes in 
this region is provided by the membership of many 
genes within the GO and Biopath functional anno-
tation groups mentioned above.
Discussion
We have demonstrated that EVA provides a 
straightforward interface for incorporating biolog-
ical knowledge into analysis of glioma microarray 
results. Using the same statistical results as 
(Rickman et al. 2001), EVA efﬁ  ciently condensed 
volumes of data into a biologically-grounded 
graphical display—facilitating independent 
corroboration of the original authors’ conclusions, 
as well as identifying novel directions for glioma 
research. This novel combination of visualization, 
statistics, and biological knowledge in a fast, user-
friendly package allowed for a truly comprehensive 
exploration of results.
EVA permits an analytical approach that is 
adaptable to the expertise or prior notions of the 
particular user and has the power to build cohesive 
conclusions supported by a collection of informa-
tion sources. These capabilities are essential for 
conﬁ  dent analysis of complex microarray data, 
which has many methodological challenges, 
including the underestimation of actual changes in 
gene expression, temporal sensitivity, and the 
selection of appropriate probe sets (Yuen et al. 
2002). A purely statistical analysis of gene expres-
sion data may give an incomplete portrayal of 
biological activity in the presence of such 
confounding issues. The multiple lines of evidence 
that EVA assembles can ameliorate some of these 
problems. EVA is ideal for efﬁ  ciently exploring 
the biology behind statistical results, identifying 
promising avenues for further experimentation, 
and augmenting evidence for hypothesized biolog-
ical models.
We anticipate EVA will be a useful addition to 
the repertoire of computational methods for micro-
array data analysis. Recent years have seen the 
development of many tools for gene expression 
analysis (Khatri et al. 2005), and while each ﬁ  lls 
a valuable analytical niche, EVA packages a set of 
exploratory tools that is appropriate for researchers 
with any level of statistical or computational exper-
tise. Research into the continued reﬁ  nement of EVA 
is ongoing. Future versions will link to additional 
gene expression databases, and EVA will be 
extended to accommodate experimental data from 
genetic and proteomic studies. The permutation 
algorithm for assessing the relative enrichment of Cancer Informatics 2007:5 24
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annotative categories will be updated to account 
for issues of multiple testing and correlation, 
following approaches similar to (Barry et al. 2005). 
EVA is available at no charge to academic users. 
More information about the continued develop-
ment of EVA can be found at http://www.epistasis.
org.
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